Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 9 METERS BIOPHARMA, INC.NMTR · Entity 114271 | Chief Financial Officer | April 21, 2023 | April 21, 2023 |
| Alpha Cognition Inc.ACOG · Entity 6339 | Director | April 16, 2026 | April 17, 2026 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Director | February 19, 2026 | February 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
9 METERS BIOPHARMA, INC.
Report date April 21, 2023 · Filed April 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 41,077 |
Reported balance
After 2023-04-21 transaction · row 1
1 source rowRow 1 · 2023-04-21 · Sale · Disposed 9,100 · Balance 41,077 F1: Reflects shares sold to cover taxes upon the vesting of restricted stock units on April 15, 2023. F2: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.23. The reporting person undertakes to provide to 9 Meters Biopharma, Inc., any security holder of 9 Meters Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares sold to cover taxes upon the vesting of restricted stock units on April 15, 2023.
F2: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.23. The reporting person undertakes to provide to 9 Meters Biopharma, Inc., any security holder of 9 Meters Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
Alpha Cognition Inc.
Report date April 16, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 5,489 |
Reported balance
After 2026-04-16 transaction · row 1
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 5,489 · Balance 5,489 F1: Restricted Stock Units that vest one year from date of grant. |
| Common Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.65 · Expires 2036-04-16 | Direct | 6,991 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 6,991 · Balance 6,991 F2: The options will vest one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units that vest one year from date of grant.
F2: The options will vest one year from date of grant.
SUPERNUS PHARMACEUTICALS, INC.
Report date February 19, 2026 · Filed February 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-02-19 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-02-19 · Exercise / conversion · Acquired 4,475 · Balance 4,475 Row 2 · 2026-02-19 · Sale · Disposed 1,217 · Balance 3,258 F1: Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.71. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Row 3 · 2026-02-19 · Sale · Disposed 3,258 · Balance 0 F1: Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.98 to $51.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-19 · Exercise / conversion · Disposed 4,475 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F5: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.71. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.98 to $51.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F5: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KalVista Pharmaceuticals, Inc.
Report date June 11, 2026 · Filed June 11, 2026
Section 16 reporting ended · disclosed 2026-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.05 · Expires 2035-09-30 | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option vests over a 3 year period: 1/36th vests on November 1, 2025, after which 1/36th of the total shares vest monthly, subject to reporting person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger").
F2: The option vests over a 3 year period: 1/36th vests on November 1, 2025, after which 1/36th of the total shares vest monthly, subject to reporting person's continued service through each vesting date.
F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 11, 2026 20:36 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | Disposition to issuerStock Option (Right to Buy) · Derivative | 45,000 | Not disclosed Strike: $12.05 | Not disclosed |
DisclosureSEC source: 0001899935-26-000007 · form4-06112026_080638.xml · derivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2035-09-30 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option vests over a 3 year period: 1/36th vests on November 1, 2025, after which 1/36th of the total shares vest monthly, subject to reporting person's continued service through each vesting date. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 19:56 UTC | Alpha Cognition Inc. ACOG · Entity 6339 | GrantCommon Share Options · Derivative | 6,991 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0000912282-26-000624 · form4.xml · derivative · entry 2 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,991 Underlying: Common Shares · 6,991 shares Expires 2036-04-16 F2 · derivative.exercise_date: The options will vest one year from date of grant. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 19:56 UTC | Alpha Cognition Inc. ACOG · Entity 6339 | GrantCommon Shares | 5,489 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000624 · form4.xml · nonDerivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,489 F1 · shares: Restricted Stock Units that vest one year from date of grant. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionRestricted Stock Unit · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001899935-26-000005 · wk-form4_1771882782.xml · derivative · entry 4 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F5 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026. F5 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,258 | $51.27 | $167,037.66 |
DisclosureSEC source: 0001899935-26-000005 · wk-form4_1771882782.xml · nonDerivative · entry 3 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.98 to $51.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 1,217 | $50.31 | $61,227.27 |
DisclosureSEC source: 0001899935-26-000005 · wk-form4_1771882782.xml · nonDerivative · entry 2 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,258 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.71. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001899935-26-000005 · wk-form4_1771882782.xml · nonDerivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 4,977 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001899935-26-000003 · wk-form4_1771623777.xml · derivative · entry 2 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 4,977 shares Expires 2036-02-18 F3 · derivative.exercise_date: Each option vests on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:43 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 2,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001899935-26-000003 · wk-form4_1771623777.xml · derivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,989 Underlying: Common Stock · 2,989 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 22:28 UTC | KalVista Pharmaceuticals, Inc. KALV · Entity 39180 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $12.05 | $0.00 |
DisclosureSEC source: 0001899935-25-000005 · form4-10022025_101017.xml · derivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-09-30 F1 · derivative.exercise_date: The option vests over a 3-year period: 1/36th vests on November 1, 2025, after which 1/36th of the total shares vest monthly, subject to reporting person's continued service through each vesting date. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:31 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,369 | $42.25 | $226,840.25 |
DisclosureSEC source: 0001628280-25-040668 · wk-form4_1755549074.xml · nonDerivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.88 to $42.52. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 22, 2025 Filed Feb 24, 2025 22:41 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007459 · wk-form4_1740436862.xml · derivative · entry 2 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,369 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F2 · derivative.exercise_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025. F2 · derivative.expiration_date: These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025. Read SEC document |
| February 22, 2025 Filed Feb 24, 2025 22:41 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007459 · wk-form4_1740436862.xml · nonDerivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,369 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:48 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007182 · wk-form4_1740174492.xml · derivative · entry 2 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,475 Underlying: Common Stock · 4,475 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:48 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,296 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-25-007182 · wk-form4_1740174492.xml · derivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,296 Underlying: Common Stock · 7,296 shares Expires 2035-02-19 F1 · derivative.exercise_date: The option vests on February 19, 2026. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 5,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027575 · tm247055-9_4seq1.xml · derivative · entry 2 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,252 | $0.00 Strike: $27.94 | $0.00 |
DisclosureSEC source: 0001104659-24-027575 · tm247055-9_4seq1.xml · derivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,252 Underlying: Common Stock · 8,252 shares Expires 2034-02-22 F1 · derivative.exercise_date: The option vests on February 22, 2025. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 21:10 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 24,153 | $0.00 Strike: $30.22 | $0.00 |
DisclosureSEC source: 0001104659-23-093982 · tm2324240-2_4seq1.xml · derivative · entry 1 Sensenig Bethany · CIK 0001899935 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,153 Underlying: Common Stock · 24,153 shares Expires 2033-08-17 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on August 17, 2024. Read SEC document |
| April 21, 2023 Filed Apr 21, 2023 17:08 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | SaleCommon stock | 9,100 | $1.21 | $11,011.00 |
DisclosureSEC source: 0001551986-23-000026 · wf-form4_168211130140021.xml · nonDerivative · entry 1 Sensenig Bethany · CIK 0001899935 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,077 F1 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on April 15, 2023. F2 · price: The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.23. The reporting person undertakes to provide to 9 Meters Biopharma, Inc., any security holder of 9 Meters Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 16:09 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | GrantCommon Stock | 50,177 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-23-000009 · primary_doc.xml · nonDerivative · entry 1 Sensenig Bethany · CIK 0001899935 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,177 F1 · price: Represents Restricted Stock Units ("RSUs") granted pursuant to the 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting date. The RSUs vest as follows: 25,089 shares vest on April 15, 2023 and 25,088 shares vest on December 31, 2023. The vesting of the December 31, 2023 RSUs will accelerate upon a change in control prior to December 31, 2023. Read SEC document |
| January 18, 2022 Filed Jan 18, 2022 19:24 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | GrantStock Option (Right to Buy) · Derivative | 1,300,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001551986-22-000011 · wf-form4_164255186024173.xml · derivative · entry 1 Sensenig Bethany · CIK 0001899935 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300,000 Underlying: Common stock · 1,300,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: 25% of these shares shall be deemed vested and exercisable on January 18, 2023 with the remainder vesting in equal monthly installments over the next 36 months, such that the option shall be fully vested on January 18, 2026, subject to the executive's continued service with the Company through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.